Drug News

Global Liquid Biopsy Market Trends Analysis 2018-2035

The liquid biopsy market is witnessing a significant surge, with the global market size estimated to be $5.4 billion in 2023 and expected to grow at a compound annual growth rate (CAGR) of 15.2% over the forecast period until 2035. This growth trajectory is propelled by escalating demand for non-invasive liquid biopsy products, primarily driven by the imperative for early cancer detection.

A recent report by ResearchAndMarkets sheds light on the burgeoning landscape of liquid biopsy, highlighting key market insights and trends shaping the industry. The report underscores the dynamic nature of the sector, with numerous companies investing substantially in research and development to capitalize on scientific advancements.

The increasing demand for liquid biopsy and other non-invasive cancer diagnostics is driven by various factors including the imperative for early cancer detection, patient monitoring, and treatment selection. Non-invasive diagnostics offer several advantages such as enhanced effectiveness of cancer treatment, reduced side effects, and decreased healthcare costs.

The liquid biopsy market is characterized by the presence of over 160 manufacturers offering more than 350 liquid biopsy products for the diagnosis of various cancer indications. Notably, the majority of these manufacturers are based in North America, with companies like ArcherDX, CellMax Life, and Personal Genome Diagnostics leading the forefront.

One of the prominent trends in the liquid biopsy market is the increasing partnerships and collaborations among stakeholders. These partnerships aim to enhance liquid biopsy product portfolios, with more than 75% of deals inked in the last three years. These collaborations predominantly focus on product/technology development agreements, reflecting the need to combine specialized technologies and expertise to create more accurate diagnostic solutions.

Furthermore, the rising interest in minimally invasive cancer diagnostics is evidenced by the substantial investments in liquid biopsy companies, amounting to close to $7.3 billion over the past four years. Venture rounds constitute the majority of the funds raised, indicating a strong investor confidence in the potential of liquid biopsy technologies.

Circulating tumor DNA (ctDNA) emerges as a key market segment, expected to hold the largest share of the liquid biopsy market. Additionally, North America and Europe are identified as the hubs of the liquid biopsy market, with Asia-Pacific projected to exhibit the fastest market growth, fueled by recent approvals and investments in the region.

In conclusion, the global liquid biopsy market presents significant opportunities for stakeholders, driven by increasing partnerships, rising investments, and growing demand for non-invasive cancer diagnostics. As the industry continues to innovate and collaborate, the future of liquid biopsy holds promise in revolutionizing cancer diagnostics and treatment.


Joan David-Leonhard

Joan David Leonhard is a recent Pharm.D graduate with a strong passion for the pharmaceutical industry and a particular interest in pharmaceutical media and communication. Her brief internship experience includes roles in pharmacy where she built strong patient-pharmacist relationships and a pharmaceutical media internship where she actively contributed to drug information articles, blog posts, social media engagement, and various media projects.
Back to top button

Adblock Detected

Please consider supporting us by disabling your ad blocker